Document is current

Article History

Received: 12 April 2024

Accepted: 28 May 2024

First Online: 1 June 2024

Competing interests

: T.P. reports receiving grants from AstraZeneca, Roche, Bristol-Myers Squibb, Exelixis, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and Eisai; consulting fees from AstraZeneca, Bristol-Myers Squibb, Exelixis, Incyte, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche, Mashup and Gilead; honoraria from AstraZeneca, Bristol-Myers Squibb, Exelixis, Incyte, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche, Mashup and Gilead; support for attending meetings and/or travel from Roche, Pfizer, MSD, AstraZeneca, Ipsen, Gilead and Astellas; holds a strategic advisory role for AstraZeneca, Bristol-Myers Squibb, Exelixis, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai and Roche; and holds a principal investigator role for Novartis, Pfizer, AstraZeneca, Roche/Genentech, Eisai and Merck. J. Munoz reports receiving honoraria for presentations from LEO pharma and GlaxoSmithKline and support for attending meetings and/or travel from LEP Pharma, GlaxoSmithKline and AstraZeneca. A.P. reports receiving consulting fees from Astellas Pharma, Janssen-Cilag, Bayer, Novartis, Merck Serono, Bristol-Myers Squibb, Eisai, MSD Oncology, Takeda, AstraZeneca and Pfizer; support for attending meetings and/or travel from Pfizer, Astellas Pharma, Bristol-Myers Squibb and MSD; and honoraria from Astellas Pharma, Janssen Oncology, Bayer, Merck Serono, Bristol-Myers Squibb, Exelixis, MSD, Medison, Roche and AstraZeneca. E.Y.Y. reports consulting for Jansen, Merck, AAA Novartis, Bayer, Aadi Bioscience, Oncternal, Bristol-Myers Squibb, Loxo, and Lantheus, and receiving research grants to his institution from Dendreon, Merck, SeaGen, Blue Earth, Bayer – DAROL and citDNA, Lantheus, Tyra, Oncternal, Daiichi-Sankyo, Taiho and Surface. A.L. reports receiving consulting fees from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Esai, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer and Roche; honoraria from Astellas, Novartis and Healthbook Company Switzerland; support for attending meetings and/or travel from Ipsen, Janssen and Bayer; and holds a leadership or fiduciary role for European Association of Urology (EAU) guidelines bladder cancer, European Society Medical Oncology (ESMO) faculty nonprostate, German Society of Hematology and Medical Oncology (DGHO) guideline bladder and testis cancer, the Swiss Group for Clinical Cancer Research (SAKK) scientific board committee and the National Center for Tumors (NCT) scientific board committee. A.B. is an employee of MSD, a subsidiary of Merck & Co., Inc., and holds stock in Merck & Co., Inc. B.H.M. is an employee of MSD, a subsidiary of Merck & Co., Inc., and holds stock in Merck & Co., Inc. J. Markensohn is an employee of MSD, a subsidiary of Merck & Co., Inc., and holds stock in Merck & Co., Inc. M.E. is an employee of MSD, a subsidiary of Merck & Co., Inc. C.C. is an employee of MSD, a subsidiary of Merck & Co., Inc., and holds stock in Merck & Co., Inc. R.C. is an employee of MSD, a subsidiary of Merck & Co., Inc., and holds stock in Merck & Co., Inc. C.P. is an employee of MSD, a subsidiary of Merck & Co., Inc., and holds stock in Merck & Co., Inc. J.L. Is an employee of MSD, a subsidiary of Merck & Co., Inc., and holds stock in Merck & Co., Inc. Y.-H.C., Y.Y., F.R-C., G.P. and S.G. have no conflicts of interest to disclose.